Nuzenio

Spyre Therapeutics

Spyre Therapeutics news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 24 latest news signals 11 publisher sources 100/100 entity strength

Latest news

Spyre Therapeutics, Inc. SEC Filing (Aug 7, 2026) - Stock TitanStock Titan · Fri, 07 Aug 2026 20:40:02 GMTSpyre Therapeutics Announces Grants of Inducement Awards - The Manila TimesThe Manila Times · Fri, 07 Aug 2026 20:26:06 GMTPrice to earnings forward of Spyre Therapeutics, Inc – DUS:3920 - TradingViewTradingView · Fri, 07 Aug 2026 07:15:31 GMTSpyre's CEO Sold Stock, but Kept 567,000 Shares. Here's What Long-Term Investors Should Know - The Motley FoolThe Motley Fool · Fri, 07 Aug 2026 00:17:00 GMTSPYRE THERAPEUTICS INC : RAYMOND JAMES RAISES TARGET PRICE TO $121 FROM $88 - webull.comwebull.com · Thu, 06 Aug 2026 23:00:50 GMTWe Think Spyre Therapeutics (NASDAQ:SYRE) Can Easily Afford To Drive Business Growth - MoomooMoomoo · Thu, 06 Aug 2026 15:16:29 GMTSpyre Therapeutics (SYRE) CEO Cameron Turtle Sells 15,000 Shares - GuruFocusGuruFocus · Thu, 06 Aug 2026 07:14:26 GMTInsider Selling: Spyre Therapeutics (NASDAQ:SYRE) CFO Sells $716,775.00 in Stock - MarketBeatMarketBeat · Thu, 06 Aug 2026 03:19:08 GMT

Timeline

Fri, 07 Aug 2026 20:40:02 GMTSpyre Therapeutics, Inc. SEC Filing (Aug 7, 2026) - Stock Titan
Fri, 07 Aug 2026 20:26:06 GMTSpyre Therapeutics Announces Grants of Inducement Awards - The Manila Times
Fri, 07 Aug 2026 07:15:31 GMTPrice to earnings forward of Spyre Therapeutics, Inc – DUS:3920 - TradingView
Fri, 07 Aug 2026 00:17:00 GMTSpyre's CEO Sold Stock, but Kept 567,000 Shares. Here's What Long-Term Investors Should Know - The Motley Fool
Thu, 06 Aug 2026 23:00:50 GMTSPYRE THERAPEUTICS INC : RAYMOND JAMES RAISES TARGET PRICE TO $121 FROM $88 - webull.com
Thu, 06 Aug 2026 15:16:29 GMTWe Think Spyre Therapeutics (NASDAQ:SYRE) Can Easily Afford To Drive Business Growth - Moomoo

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Spyre Therapeutics.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

11 distinct publisher/source names are currently connected to this entity page.